Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jun 29

PMID 31248118

Citations 45

Authors

Monique K van der Kooij

Frank M Speetjens

Sjoerd H van der Burg

Ellen Kapiteijn

Affiliations

Soon will be listed here.

Abstract

Here, we critically evaluated the knowledge on cutaneous melanoma (CM) and uveal melanoma (UM). Both cancer types derive from melanocytes that share the same embryonic origin and display the same cellular function. Despite their common origin, both CM and UM display extreme differences in their genetic alterations and biological behavior. We discuss the differences in genetic alterations, metastatic routes, tumor biology, and tumor-host interactions in the context of their clinical responses to targeted- and immunotherapy.

Citing Articles

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.

Gouda M, Zarifa A, Yang Y, Stephen B, Gurses S, Sprenger A J Immunother Precis Oncol. 2025; 8(1):82-88.

PMID: 39816915 PMC: 11728387. DOI: 10.36401/JIPO-24-10.

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Szczygielski O, Dabrowska E, Niemyjska S, Przylipiak A, Zajkowska M Int J Mol Sci. 2025; 25(24.

PMID: 39769318 PMC: 11676509. DOI: 10.3390/ijms252413558.

Overcoming Resistance Mechanisms to Melanoma Immunotherapy.

Zheng D, Bozym D, Tarantino G, Sullivan R, Liu D, Jenkins R Am J Clin Dermatol. 2024; 26(1):77-96.

PMID: 39636504 DOI: 10.1007/s40257-024-00907-7.

Proton Therapy in Uveal Melanoma.

Chan A, Lin H, Yacoub I, Chhabra A, Choi J, Simone 2nd C Cancers (Basel). 2024; 16(20).

PMID: 39456591 PMC: 11506608. DOI: 10.3390/cancers16203497.

Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases.

Karlsson J, Sah V, Olofsson Bagge R, Kuznetsova I, Iqba M, Alsen S Elife. 2024; 12.

PMID: 39312285 PMC: 11419671. DOI: 10.7554/eLife.91705.

References

Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R . Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013; 24(11):2911-5. DOI: 10.1093/annonc/mdt376. View

Staby K, Gravdal K, Mork S, Heegaard S, Vintermyr O, Krohn J . Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. Acta Ophthalmol. 2017; 96(1):31-38. DOI: 10.1111/aos.13452. View

Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S . CCR4 is a determinant of melanoma brain metastasis. Oncotarget. 2017; 8(19):31079-31091. PMC: 5458190. DOI: 10.18632/oncotarget.16076. View

Falleni M, Savi F, Tosi D, Agape E, Cerri A, Moneghini L . M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma. Melanoma Res. 2017; 27(3):200-210. DOI: 10.1097/CMR.0000000000000352. View

Weber J, Smalley K, Sondak V, Gibney G . Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res. 2013; 19(22):6329-30. PMC: 4666498. DOI: 10.1158/1078-0432.CCR-13-2007. View

Scotton C, Wilson J, Scott K, Stamp G, Wilbanks G, Fricker S . Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002; 62(20):5930-8. View

Beadling C, Jacobson-Dunlop E, Hodi F, Le C, Warrick A, Patterson J . KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008; 14(21):6821-8. DOI: 10.1158/1078-0432.CCR-08-0575. View

de Lange M, Nell R, Lalai R, Versluis M, Jordanova E, Luyten G . Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. Mol Cancer Res. 2018; 16(12):1902-1911. DOI: 10.1158/1541-7786.MCR-18-0114. View

Hornig E, Heppt M, Graf S, Ruzicka T, Berking C . Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. Exp Dermatol. 2016; 25(11):831-838. DOI: 10.1111/exd.13089. View

10.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

11.

Yu P, Fu Y . Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest. 2006; 86(3):231-45. DOI: 10.1038/labinvest.3700389. View

12.

Spathis A, Katoulis A, Damaskou V, Liakou A, Kottaridi C, Leventakou D . Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters. Dermatol Pract Concept. 2019; 9(1):54-62. PMC: 6368075. DOI: 10.5826/dpc.0901a13. View

13.

Ihle M, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N . Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014; 14:13. PMC: 3893431. DOI: 10.1186/1471-2407-14-13. View

14.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

15.

Landreville S, Agapova O, Matatall K, Kneass Z, Onken M, Lee R . Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2011; 18(2):408-16. PMC: 3261307. DOI: 10.1158/1078-0432.CCR-11-0946. View

16.

Algazi A, Tsai K, Shoushtari A, Munhoz R, Eroglu Z, Piulats J . Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122(21):3344-3353. PMC: 5767160. DOI: 10.1002/cncr.30258. View

17.

van Essen T, van Pelt S, Bronkhorst I, Versluis M, Nemati F, Laurent C . Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes. PLoS One. 2016; 11(10):e0164292. PMC: 5072555. DOI: 10.1371/journal.pone.0164292. View

18.

Economou M, All-Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O . Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005; 46(12):4372-5. DOI: 10.1167/iovs.05-0322. View

19.

Kottschade L, McWilliams R, Markovic S, Block M, Bisneto J, Pham A . The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016; 26(3):300-3. DOI: 10.1097/CMR.0000000000000242. View

20.

Daud A, Kluger H, Kurzrock R, Schimmoller F, Weitzman A, Samuel T . Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017; 116(4):432-440. PMC: 5318966. DOI: 10.1038/bjc.2016.419. View